Gubra announces that a clinical trial application (CTA) for the anti-obesity amylin project has been submitted to the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK. The clinical trial is expected to receive approval from the MHRA later…
On 28 August 2023, Gubra A/S (“Gubra” or the “Company”) announced resumption of its share buy-back programme of in total 27,271 shares. The purpose of the share buy-back programme is to meet the Company’s obligations arising from its share-based incentive…
Gubra A/S (“Gubra” or the “Company”) today announces the resumption of its share buy-back programme, pursuant to which the Company intends to buy back up to 27,231 of its own shares. As 1,539 shares were repurchased during 30 June to…
Today, Gubra released its interim report for the first half of 2023. Organic revenue grew by 21% year-over-year for the CRO business with an adjusted EBIT-margin of 27%. FY-2023 outlook for organic revenue growth was, as communicated on 15 August…
Today we publish our interim report focusing closely on the performance of the company the first six months of 2023. Watch this video with CEO of Gubra Henrik Blou where he covers most of it in 3 minutes. Contacts at…
Gubra and Bayer started the collaboration in 2021 Gubra will actively (alone or with a new partner) continue further development of the cardio-renal metabolic peptide programme Gubra sees great potential for this drug programme within the area of healthy weight…
Today, Gubra announces the signing of an agreement with Hemab concerning a peptide collaboration. Under the terms of this pre-collaboration agreement, Gubra will start working on identifying peptide modulators suitable as a treatment for certain bleeding disorders. Gubra will utilize…
Today, Gubra announces preliminary Q2 and H1 2023 revenue figures for the CRO business and revises its revenue outlook for 2023 upwards, driven by strong performance in Q2 2023 as well as current trading and solid orderbook. The 2023 outlook…
On 30 June, 2023, Gubra A/S (“Gubra” or the “Company”) announced that a share buy-back programme of approximately DKK 2.5 million and up to a maximum of 27,231 shares has been initiated with the purpose of meeting the Company's obligations…
Gubra A/S (“Gubra” or the “Company”) today announces the initiation of a share buy-back programme, pursuant to which the Company intends to buy back up to 27,231 of its own shares. The purpose of the share buy-back programme is to…